Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

BDTX
Black Diamond Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
May 9, 2025 3:59:48 PM EDT
1.64USD-2.959%(-0.05)641,986
1.63Bid   1.64Ask   0.01Spread
Pre-market
May 9, 2025 9:22:30 AM EDT
1.70USD+0.592%(+0.01)2,888
After-hours
May 9, 2025 4:49:30 PM EDT
1.62USD-1.220%(-0.02)4,539
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
08:36AM EST  The Daily Biotech Pulse: Illumina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In   Benzinga
07:10AM EST  Black Diamond Therapeutics Announces FDA Allowance Of IND Application For BDTX-153 For Gliobastoma And NSCLC   RTTNews
07:02AM EST  Black Diamond Therapeutics Announces FDA Allowance Of IND Application For BDTX-1535, A MasterKey Inhibitor Of EGFR for Treatment Of Gliobastoma And Non-Small Cell Lung Cancer   Benzinga
07:00AM EST  Black Diamond Therapeutics Announces FDA Allowance of IND   GlobeNewswire Inc
Jan 10, 2022
07:00AM EST  Black Diamond Therapeutics Announces Strategic Priorities and   GlobeNewswire Inc
Jan 5, 2022
08:00AM EST  Black Diamond Therapeutics to Present at the 40th Annual J.P.   GlobeNewswire Inc
Nov 8, 2021
04:05PM EST  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Companys progress at the following upcoming investor conferences:   GlobeNewswire Inc
07:45AM EST  Black Diamond Therapeutic Q3 EPS $(0.97) Down From $(0.50) YoY   Benzinga
07:45AM EST  Black Diamond Therapeutics Reports Third Quarter 2021 Financial   GlobeNewswire Inc
Oct 8, 2021
04:06PM EDT  Black Diamond Therapeutics Highlights Presentation Of Preclinical Data On BDTX-1535, B-Raf, Fibroblast Growth Factor Receptor Programs At AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics   Benzinga
04:05PM EDT  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the presentation of preclinical data for three early-stage pipeline programs in oral and poster sessions at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.   GlobeNewswire Inc
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Oct 1, 2021
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 30, 2021
04:36PM EDT  Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics   Benzinga
04:35PM EDT  Black Diamond Therapeutics to Present Pre-Clinical Data on   GlobeNewswire Inc
11:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021   Benzinga
04:54AM EDT  Stifel Initiates Coverage On Black Diamond Therapeutic with Hold Rating, Announces Price Target of $10   Benzinga
Sep 21, 2021
04:10PM EDT  Black Diamond Therapeutics To Present At 2021 Cantor Fitzgerald Virtual Global Healthcare Conference Sept. 28 At 4:40 p.m. ET   Benzinga
04:05PM EDT  Black Diamond Therapeutics to Present at the 2021 Cantor   GlobeNewswire Inc
07:45AM EDT  Strategic partnership between Black Diamond and OpenEye aims to accelerate drug discovery efforts through cloud-based molecular dynamics technology   GlobeNewswire Inc
Aug 12, 2021
08:36AM EDT  Black Diamond Therapeutic Q2 EPS $(0.95) Down From $(0.41) YoY   Benzinga
08:22AM EDT  Black Diamond Therapeutics Reports Second Quarter 2021 Financial   GlobeNewswire Inc
Aug 10, 2021
07:45AM EDT  Black Diamond Therapeutics Announces Appointment of Mark Velleca,   GlobeNewswire Inc
Aug 4, 2021
07:45AM EDT  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Companys progress at the following upcoming investor conferences:   GlobeNewswire Inc
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jul 7, 2021
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jun 23, 2021
07:35AM EDT  The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway   Benzinga
Jun 3, 2021
08:23AM EDT  The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout   Benzinga
Jun 2, 2021
08:20AM EDT  The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements   Benzinga
May 27, 2021
08:24AM EDT  The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs   Benzinga
May 25, 2021
07:53AM EDT  The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal   Benzinga
May 21, 2021
07:26AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying   Benzinga
May 20, 2021
02:31PM EDT  Mid-Afternoon Market Update: Dow Jumps 230 Points; Kohl's Shares Plummet   Benzinga
12:21PM EDT  Mid-Day Market Update: Nasdaq Surges 200 Points; Black Diamond Therapeutics Shares Slide   Benzinga
10:13AM EDT  Mid-Morning Market Update: Markets Rise; Hormel Foods Beats Q2 Views   Benzinga
08:27AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks   Benzinga
May 19, 2021
05:00PM EDT  Once-daily (QD) dose escalation completed; pharmacokinetic (PK) profile consistent with design principles and preclinical predictions   GlobeNewswire Inc
May 17, 2021
07:45AM EDT  Company to host conference call on Wednesday, May 19, 2021 at 6:00 PM ET   GlobeNewswire Inc
May 7, 2021
07:47AM EDT  Black Diamond Therapeutic Q1 EPS $(0.84) Down From $(0.51) YoY   Benzinga
07:45AM EDT  Black Diamond Therapeutics Reports First Quarter 2021 Financial   GlobeNewswire Inc
Apr 28, 2021
10:39AM EDT  Black Diamond Therapeutics To Present Phase 1 BDTX-189 Data In Advanced Solid Tumors At American Society of Clinical Oncology   Benzinga
10:38AM EDT  Initial pharmacokinetic (PK), safety, and preliminary efficacy data from Phase 1 dose-escalation portion of MasterKey-01 clinical trial to be presented   GlobeNewswire Inc
Apr 12, 2021
10:29AM EDT  Black Diamond Therapeutics Saturday Morning Announced Preclinical Data Presentations On BDTX-189, BDTX-1535 At American Association For Cancer Research Conference   Benzinga
Apr 10, 2021
08:30AM EDT  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced the presentation of preclinical data on BDTX-189 and BDTX-1535 at the American Association for Cancer Research Annual Meeting (AACR), taking place April 9-14, 2021.   GlobeNewswire Inc
Mar 25, 2021
11:01AM EDT  Black Diamond Therapeutic shares were trading higher after the company reported Q4 EPS of $(0.63), up from $(4.63) year over year.   Benzinga
07:46AM EDT  Black Diamond Therapeutic Q4 EPS $(0.63) Up From $(4.63) YoY   Benzinga
07:45AM EDT  Black Diamond Therapeutics Reports Fourth Quarter and Full Year   GlobeNewswire Inc
Mar 15, 2021
07:43AM EDT  Black Diamond Therapeutics Announces FDA Notified Co. That It May Only Enroll Up To 50 Patients In Phase 2 of BDTX-189; Co. Announces 'The Company has initiated the GLP toxicology studies and does not anticipate any delays to its clinical trial timelines'   Benzinga
Mar 10, 2021
05:01PM EST  Black Diamond Therapeutics To Present Pre-Clinical Data On BDTX-189 and BDTX-1535 At American Association For Cancer Research Annual Meeting   Benzinga
04:59PM EST  Black Diamond Therapeutics to Present Pre-Clinical Data on   GlobeNewswire Inc
Mar 2, 2021
04:26PM EST  Black Diamond Therapeutics Highlights Pre-Clinical Data Presentations On New Programs Targeting BRAF And FGFR At ESMO TAT Virtual Congress 2021   Benzinga
04:05PM EST  Black Diamond Therapeutics Announces Pre-Clinical Data   GlobeNewswire Inc
Feb 23, 2021
07:45AM EST  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Companys progress at the following upcoming investor conferences:   GlobeNewswire Inc
Feb 11, 2021
04:15PM EST  Black Diamond Therapeutics to Present at the BMO Biopharma   GlobeNewswire Inc
Jan 20, 2021
07:45AM EST  Black Diamond Therapeutics Announces Appointment of Oncology   GlobeNewswire Inc
Jan 12, 2021
10:22AM EST  Mid-Morning Market Update: Markets Edge Higher; Albertsons Earnings Beat Expectations   Benzinga
Jan 7, 2021
12:10PM EST  Benzinga's Top Upgrades, Downgrades For January 7, 2021   Benzinga
06:26AM EST  Wedbush Initiates Coverage On Black Diamond Therapeutic with Outperform Rating   Benzinga
Jan 5, 2021
07:45AM EST  Black Diamond Therapeutics to Present at the J.P. Morgan 39th   GlobeNewswire Inc
Nov 24, 2020
09:51AM EST  Benzinga's Top Upgrades, Downgrades For November 24, 2020   Benzinga
08:23AM EST  Berenberg Initiates Coverage On Black Diamond Therapeutic with Buy Rating, Announces Price Target of $58   Benzinga
07:45AM EST  Black Diamond Therapeutics to Present at the Piper Sandler 32nd   GlobeNewswire Inc
Nov 20, 2020
07:49AM EST  Black Diamond Therapeutics Highlights Presentation At 2020 SNO Annual Meeting   Benzinga
07:45AM EST  -- BDTX-1535 nominated as development candidate with IND-enabling studies underway -- Pre-clinical data supportnovel and differentiated approach in GBM   GlobeNewswire Inc
Nov 11, 2020
07:45AM EST  Black Diamond Therapeutics to Present at the Jefferies 2020   GlobeNewswire Inc
Nov 10, 2020
07:50AM EST  Black Diamond Therapeutic Q3 EPS $(0.50) Up From $(4.50) YoY   Benzinga
07:49AM EST  Black Diamond Therapeutics Q3 Loss/Shr $0.50 Vs Loss $4.50 Last Year   RTTNews
07:45AM EST  Black Diamond Therapeutics Reports Third Quarter 2020 Financial   GlobeNewswire Inc
Oct 26, 2020
07:46AM EDT  Black Diamond Therapeutics Highlights Presentation Of Pre-Clinical Data On Lead Product Candidate BDTX-189 At 32nd EORTC-NCI-AACR Virtual Symposium   Benzinga
07:45AM EDT  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the presentation of pre-clinical data on the Companys lead product candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020).   GlobeNewswire Inc
Oct 12, 2020
07:48AM EDT  Black Diamond Therapeutics to Present Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium   Benzinga
07:45AM EDT  Black Diamond Therapeutics to Present Pre-Clinical Data on Lead   GlobeNewswire Inc
Sep 29, 2020
07:48AM EDT  Black Diamond Therapeutics Announces Appointment Of Robert A. Ingram As Chairman Of The Board   Benzinga
07:45AM EDT  Black Diamond Therapeutics Announces the Appointment   GlobeNewswire Inc
Sep 8, 2020
04:12PM EDT  Black Diamond Therapeutics Appoints Rachel Humphrey As Chief Medical Officer   RTTNews
04:07PM EDT  Black Diamond Therapeutics Announces The Appointment Of Rachel Humphrey As Chief Medical Officer   Benzinga
04:05PM EDT  Black Diamond Therapeutics Announces the Appointment of Rachel   GlobeNewswire Inc
Aug 11, 2020
07:45AM EDT  Black Diamond Therapeutics Reports Second Quarter 2020 Financial   GlobeNewswire Inc
07:26AM EDT  Black Diamond Therapeutic Q2 EPS $(0.41) Up From $(5.99) YoY   Benzinga
Aug 5, 2020
07:45AM EDT  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Companys progress at the following upcoming investor conferences:   GlobeNewswire Inc
Aug 4, 2020
08:00AM EDT  Black Diamond Therapeutics Appoints Fang Ni As Chief Business Officer   RTTNews
07:45AM EDT  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Fang Ni, Pharm.D., as Chief Business Officer.   GlobeNewswire Inc
Jul 28, 2020
10:03AM EDT  Black Diamond Therapeutics shares are trading higher after the company was granted Fast Track designation by the FDA for BDTX-189 for treatment of adult patients with a solid tumor harboring an allosteric HER2 mutation or an EGFR or HER2 Exon 20 Insertion UPDATE: Shares have since reversed, now lower.   Benzinga
07:46AM EDT  Black Diamond Therapeutics Granted Fast Track Designation By FDA For BDTX-189 For Treatment Of Adult Patients With A Solid Tumor Harboring An Allosteric HER2 Mutation Or An EGFR Or HER2 Exon 20 Insertion Mutation   Benzinga
07:45AM EDT  Black Diamond Therapeutics Granted Fast Track Designation by the   GlobeNewswire Inc
Jul 27, 2020
10:40AM EDT  Shares of Black Diamond Therapeutics, Inc. (BDTX) are trading nearly 13% higher on Monday morning despite no stock-related news to help the shares.   RTTNews


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC